A markedly higher rate of either BRAF mutations (59%) or CyclinD1 (38%) or cKIT (13%) amplifications was previously observed in 32 melanoma cell lines as controls by our group ([45] and unpublished data). This evidence concerns the gene KIT and melanoma.